| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of our study is to develop a clinically relevant orthotopic xenotransplantation model of pancreatic cancer that reflects the clinical situation and, to perform the preclinical evaluation of new diagnostic and therapeutic PET imaging probes, allowed in this model. At first, we succeeded to establish the orthotopic pancreatic cancer xenograft model. Next, among three candidates of PET imaging probes (64Cu-RAFT-RGD, 11C-Sorafenib, 11C-DAC), we put focus on the 64Cu-RAFT-RGD probe and performed in vitro and in vivo experiments, small animal 64Cu-RAFT-RGD PET imaging comparing with 18F-FDG-PET, contrasted CT (CECT) after PET, and examined the potential applicability of probe. Postimaging autoradiography, histologic, immunohistochemical and immunofluorescence examinations, and the comprehensive results suggested that 64Cu-RAFT-RGD possesses the specific binding to αvβ3 integrin of pancreatic tumor cells and may provide higher detectability over 18F-FDG-PET.
|
